Biotechnology company Psiron Ltd is pleased to announce the achievement of three important milestones in the cancer research program being undertaken at the University of Newcastle under Associate Professor Darren Shafren.
The three milestones are: - Breast cancer: identification of a lead candidate, - Prostate cancer: identification of a lead candidate, and - Colorectal cancer: identification of a lead candidate.
Using different types of cells of each of these cancers, the researchers have tested a range of viruses to determine which virus kills the cancer most effectively in the laboratory. These data have been reviewed by Psiron’s Scientific Advisory Board.
The next stage of research will use these viruses in animal experiments for demonstration of “proof of concept” as has already been done with Echovirus-1 in ovarian cancer.
Achievement of these research milestones triggers allocation of 1.5 million shares to technology licensor, ViroTarg Pty Ltd.
Stephen Jones Executive Chairman _________________________________________________________________________________ ISSUED FOR : PSIRON Ltd (ASX CODE: PSX), WEBSITE: www.psiron.com FOR FURTHER INFORMATION : MS JULIE NUTTING, CEO, PSIRON LTD, TEL: 61 2 9889 1200 ISSUED BY : WESTBROOK COMMUNICATIONS ` CONTACT: DAVID REID, TEL: 612 9231 0922 (BUS), 0417 217 157 (MOB)
A copy of this release can be downloaded from www.westbrookfin.com.au
